Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 650

1.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators.

N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.

2.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
3.

Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.

Tashkin DP.

Expert Rev Respir Med. 2010 Jun;4(3):279-89. doi: 10.1586/ers.10.23. Review.

PMID:
20524910
4.

COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).

Morice AH, Celli B, Kesten S, Lystig T, Tashkin D, Decramer M.

Respir Med. 2010 Nov;104(11):1659-67. doi: 10.1016/j.rmed.2010.07.016. Epub 2010 Aug 17.

5.

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.

Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S.

Thorax. 2003 May;58(5):399-404. Erratum in: Thorax. 2005 Feb;60(2):105.

6.

Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial.

Fukuchi Y, Fernandez L, Kuo HP, Mahayiddin A, Celli B, Decramer M, Kesten S, Liu D, Tashkin D.

Respirology. 2011 Jul;16(5):825-35. doi: 10.1111/j.1440-1843.2011.01982.x. Erratum in: Respirology. 2011 Nov;16(8):1281.

PMID:
21539680
7.

Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.

Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M; Uplift Investigators.

Eur Respir J. 2010 Jul;36(1):65-73. doi: 10.1183/09031936.00127809. Epub 2010 Feb 25.

8.

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.

Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators.

Lancet. 2009 Oct 3;374(9696):1171-8. doi: 10.1016/S0140-6736(09)61298-8. Epub 2009 Aug 27.

PMID:
19716598
9.

Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance.

Ambrosino N, Foglio K, Balzano G, Paggiaro PL, Lessi P, Kesten S; Tiotropium Multicentric Italian Study Group.

Int J Chron Obstruct Pulmon Dis. 2008;3(4):771-80.

10.

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.

Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.

Ann Intern Med. 2007 Apr 17;146(8):545-55. Epub 2007 Feb 19.

PMID:
17310045
11.

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.

Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, Cassino C, Kesten S.

Ann Intern Med. 2005 Sep 6;143(5):317-26.

PMID:
16144890
12.

Exacerbation frequency and course of COPD.

Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP.

Int J Chron Obstruct Pulmon Dis. 2012;7:653-61. doi: 10.2147/COPD.S34186. Epub 2012 Sep 21.

13.
14.

Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease.

Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S.

Thorax. 2003 Oct;58(10):855-60.

15.

Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial.

Tashkin DP, Celli BR, Decramer M, Lystig T, Liu D, Kesten S.

COPD. 2012 Jun;9(3):289-96. doi: 10.3109/15412555.2012.656211. Epub 2012 Mar 20.

PMID:
22432932
16.

The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease.

Verkindre C, Bart F, Aguilaniu B, Fortin F, Guérin JC, Le Merre C, Iacono P, Huchon G.

Respiration. 2006;73(4):420-7. Epub 2005 Nov 7.

PMID:
16484769
17.

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators.

N Engl J Med. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.

18.

Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids.

Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW.

Respirology. 2006 Sep;11(5):598-602.

PMID:
16916333
20.

Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.

Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD; Korean Academy of Tuberculosis and Respiratory Diseases study group; Korea Chronic Obstructive Pulmonary Disease study group.

Respir Med. 2012 Mar;106(3):382-9. doi: 10.1016/j.rmed.2011.09.004. Epub 2011 Oct 4.

Supplemental Content

Support Center